StockCIK 1936258
NewAmsterdam Pharma Co N.V. (NAMS): Insider Trades and Fund Holdings
In the past 12 months, NewAmsterdam Pharma Co N.V. insiders reported 1 open-market purchase worth $227K and 3 sales worth $4.66M; 2 of the sales were reported as made under a 10b5-1 trading plan.
1Insider buys, 12 months
$227KBought by insiders, 12 months
$4.66MSold by insiders, 12 months
2Tracked funds holding
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 2, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Oct 2 | Johannes Jacob Pieter KasteleinChief Scientific Officer | ▼ SELL10b5-1 | $1.26M |
| Sep 15 | Michael H. DavidsonCEO | ▲ BUY | $227K |
| Sep 9 | John W. SmitherDirector | ▼ SELL | $41K |
| Aug 25 | Johannes Jacob Pieter KasteleinChief Scientific Officer | ▼ SELL10b5-1 | $3.36M |
Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Johannes Jacob Pieter Kastelein | Chief Scientific Officer | 0 | $0 | 2 | $4.62M |
| Michael H. Davidson | CEO | 1 | $227K | 0 | $0 |
| John W. Smither | Director | 0 | $0 | 1 | $41K |
ADVERTISEMENT
320 × 100 ad slot
Tracked funds that report NAMS
From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.
| Fund | Shares | Value | Change |
|---|---|---|---|
| Viking Global Investors | 4,203,567 | $142.5M | No change |
| Duquesne Family Office | 3,070,146 | $104K | No change |
Source: SEC Form 13F-HR filings, retrieved Oct 28, 2026. How we read filings
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →